Clinical Trials Logo

Lymphoblastic Lymphoma clinical trials

View clinical trials related to Lymphoblastic Lymphoma.

Filter by:

NCT ID: NCT00412243 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the drugs clofarabine and cyclophosphamide that can be given together in the treatment of relapsed or refractory ALL. The safety of the combination treatment will also be studied. Objectives: Phase I: 1. To establish toxicities and safety of the proposed combination 2. To establish the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the combination to proceed with the phase II part of the study Phase II: 3. To establish the efficacy (complete and overall response) of the proposed combination. 4. To analyze pharmacokinetic (PK) and pharmacodynamic (PD) properties of clofarabine as well as the impact on DNA repair of leukemic blasts with the proposed combination.

NCT ID: NCT00199082 Completed - Clinical trials for Lymphoblastic Lymphoma

Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

Start date: July 2002
Phase: Phase 4
Study type: Interventional

The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is offered for patients estimated to be over 55 years, biologically.

NCT ID: NCT00187122 Completed - Clinical trials for Lymphoblastic Lymphoma

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Start date: March 1993
Phase: N/A
Study type: Interventional

The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.